rocket pharma - Search News

Order byBest matchMost fresh

News

Patient Death In Rocket Pharma Trial Triggers Downgrades

Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty

Rocket Pharmaceuticals Inc (NASDAQ:RCKT) on Tuesday announced an update related to RP-A501, its investigational gene therapy for Danon disease, a rare X-linked dominant genetic disorder that manifests with the clinical triad of cardiomyopathy (stiff heart muscles),

Continue reading

· 1d · on MSN

FDA halts Rocket Pharma's gene therapy trial as complications lead to patient death

Stocktwits on MSN · 23h

Patient Death In Rocket Pharma Trial Triggers Downgrades, But Retail Traders Bet Big On Strong Recovery

11h

Rocket Pharmaceuticals: Despite FDA Clinical Hold On RP-A501, Prospects Remain Intact

FDA places clinical hold of RP-A501 for the treatment of patients with Danon disease due to a patient death. Click here to ...

17h

These Analysts Slash Their Forecasts On Rocket Pharmaceuticals

Rocket Pharmaceuticals Inc RCKT +2.58% + Free Alerts announced an update Tuesday related to RP-A501, its investigational gene ...

1d

CoreWeave, Rocket Pharmaceuticals, SoundHound: Trending Tickers

Barclays analysts downgraded CoreWeave (CRWV) to Equal Weight, raising valuation concerns. This is CoreWeave's first ...

12hon MSN

William Blair Reaffirms Outperform Rating on Rocket Pharma Despite Trial Setback

Sami Corwin, an analyst at William Blair, maintained his Outperform rating on Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) on ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results